HIHeini Ilves

Heini Ilves

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heini Ilves has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds

    by Brandon J. Sumpio, Anne Dallas, Adam G. Berger, Zhuqing Li, Enya Wang, Ikram Mezghani, Mauricio Contreras, Georgios Theocharidis, Heini Ilves, Paula T. Hammond, et al.

    Objective: To evaluate the efficacy of layer-by-layer (LbL) formulated therapeutic RNAs that inhibit PHD2 and microRNA-210 (miR-210), to improve impaired diabetic wound healing. Approach: We employed the diabetic neuroischemic rabbit model of impaired wound healing. Diabetes was induced in the rabbits with alloxan, and neuroischemia was induced by ligating the central neurovascular bundle of each ear. Four 6-mm full-thickness wounds were creating on each ear. A layer-by-layer (LbL) technique was employed to conformally coat the wound dressings with a chemically modified antisense RNA (antimiR) against miR-210 and an sshRNA targeting PHD2. Results: Wound healing was improved by the antimiR-210 but not the PHD2-sshRNA. Specific knockdown of miR-210 in tissue as measured by RT-qPCR was approximately 8 Ct greater than nonspecific controls, and this apparent level of knockdown (>99%) suggests that delivery to the tissue is highly efficient at the administered dose. Innovation: Use of novel therapeutic RNAs and the LbL system to deliver them to the diabetic wound. Conclusion: Healing of ischemic/neuropathic wounds in diabetic rabbits was accelerated upon inhibition of miR-210 by LbL delivery to the wound bed of a chemically modified antisense RNA targeting this microRNA.


  • Open Access

    Correction: Chhalliyil et al. A Real-Time Quantitative PCR Method Specific for Detection and Quantification of the First Commercialized Genome-Edited Plant. Foods 2020, 9, 1245

    by Pradheep Chhalliyil, Heini Ilves, Sergei A. Kazakov, Stephanie J. Howard, Brian H. Johnston, John Fagan

    The stated objective of the paper was to provide regulatory laboratories and industry laboratories a complete, legally robust method for the quantitative detection of SU canola


  • Open Access

    A Real-Time Quantitative PCR Method Specific for Detection and Quantification of the First Commercialized Genome-Edited Plant

    by Pradheep Chhalliyil, Heini Ilves, Sergei A. Kazakov, Stephanie J. Howard, Brian H. Johnston, John Fagan

    Discussion regarding the regulatory status of genome-edited crops has focused on precision of editing and on doubts regarding the feasibility of analytical monitoring compliant with existing GMO regulations. Effective detection methods are important, both for regulatory enforcement and traceability in case of biosafety, environmental or socio-economic impacts. Here, we approach the analysis question for the first time in the laboratory and report the successful development of a quantitative PCR detection method for the first commercialized genome-edited crop, a canola with a single base pair edit conferring herbicide tolerance. The method is highly sensitive and specific (quantification limit, 0.05%), compatible with the standards of practice, equipment and expertise typical in GMO laboratories, and readily integrable into their analytical workflows, including use of the matrix approach. The method, validated by an independent laboratory, meets all legal requirements for GMO analytical methods in jurisdictions such as the EU, is consistent with ISO17025 accreditation standards and has been placed in the public domain. Having developed a qPCR method for the most challenging class of genome edits, single-nucleotide variants, this research suggests that qPCR-based method development may be applicable to virtually any genome-edited organism. This advance resolves doubts regarding the feasibility of extending the regulatory approach currently employed for recombinant DNA-based GMOs to genome-edited organisms.